Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1794–1799. doi: 10.1038/sj.bjc.6990286

A novel immunoscintigraphy technique using metabolizable linker with angiotensin II treatment

Y Nakamoto 1, H Sakahara 1, T Saga 1, N Sato 1, S Zhao 1, Y Arano 2, Y Fujioka 2, H Saji 2, J Konishi 1
PMCID: PMC2362799  PMID: 10206295

Abstract

Immunoscintigraphy is a tumour imaging technique that can have specificity, but high background radioactivity makes it difficult to obtain tumour imaging soon after the injection of radioconjugate. The aim of this study is to see whether clear tumour images can be obtained soon after injection of a radiolabelled reagent using a new linker with antibody fragments (Fab), in conditions of induced hypertension in mice. Fab fragments of a murine monoclonal antibody against human osteosarcoma were labelled with radioiodinated 3′-iodohippuryl N-ɛ-maleoyl-L-lysine (HML) and were injected intravenously to tumour-bearing mice. Angiotensin II was administered for 4 h before and for 1 h after the injection of radiolabelled Fab. Kidney uptake of 125I-labelled-HML-Fab was much lower than that of 125I-labelled-Fab radioiodinated by the chloramine-T method, and the radioactivity of tumour was increased approximately two-fold by angiotensin II treatment at 3 h after injection, indicating high tumour-to-normal tissue ratios. A clear tumour image was obtained with 131I-labelled-HML-Fab at 3 h post-injection. The use of HML as a radiolabelling reagent, combined with angiotensin II treatment, efficiently improved tumour targeting and enabled the imaging of tumours. These results suggest the feasibility of PET scan using antibody fragment labelled with 18F-fluorine substitute for radioiodine. © 1999 Cancer Research Campaign

Keywords: monoclonal antibody, tumour imaging, metabolizable linker, angiotensin, induced hypertension

Full Text

The Full Text of this article is available as a PDF (126.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arano Y., Inoue T., Mukai T., Wakisaka K., Sakahara H., Konishi J., Yokoyama A. Discriminated release of a hippurate-like radiometal chelate in nontarget tissues for target-selective radioactivity localization using pH-dependent dissociation of reduced antibody. J Nucl Med. 1994 Feb;35(2):326–333. [PubMed] [Google Scholar]
  2. Collier B. D., Abdel-Nabi H., Doerr R. J., Harwood S. J., Olsen J., Kaplan E. H., Winzelberg G. G., Grossman S. J., Krag D. N., Mitchell E. P. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology. 1992 Oct;185(1):179–186. doi: 10.1148/radiology.185.1.1523304. [DOI] [PubMed] [Google Scholar]
  3. Corbisiero R. M., Yamauchi D. M., Williams L. E., Esteban J. M., Odom-Maryon T., Beatty J. D. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res. 1991 Oct 15;51(20):5704–5711. [PubMed] [Google Scholar]
  4. GREENWOOD F. C., HUNTER W. M., GLOVER J. S. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J. 1963 Oct;89:114–123. doi: 10.1042/bj0890114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Garg P. K., Garg S., Bigner D. D., Zalutsky M. R. Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model. Cancer Res. 1992 Sep 15;52(18):5054–5060. [PubMed] [Google Scholar]
  6. Gasparini M., Buraggi G. L., Regalia E., Maffioli L., Balzarini L., Gennari L. Comparison of radioimmunodetection with other imaging methods in evaluating local relapses of colorectal carcinoma. Cancer. 1994 Feb 1;73(3 Suppl):846–849. doi: 10.1002/1097-0142(19940201)73:3+<846::aid-cncr2820731315>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  7. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  8. Hnatowich D. J., Virzi F., Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987 Aug;28(8):1294–1302. [PubMed] [Google Scholar]
  9. Hori K., Suzuki M., Abe I., Saito S., Sato H. Increase in tumor vascular area due to increased blood flow by angiotensin II in rats. J Natl Cancer Inst. 1985 Feb;74(2):453–459. [PubMed] [Google Scholar]
  10. Hori K., Suzuki M., Tanda S., Saito S. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res. 1990 Mar;81(3):279–288. doi: 10.1111/j.1349-7006.1990.tb02562.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hori K., Zhang Q. H., Saito S., Tanda S., Li H. C., Suzuki M. Microvascular mechanisms of change in tumor blood flow due to angiotensin II, epinephrine, and methoxamine: a functional morphometric study. Cancer Res. 1993 Nov 15;53(22):5528–5534. [PubMed] [Google Scholar]
  12. Hosoi S., Nakamura T., Higashi S., Yamamuro T., Toyama S., Shinomiya K., Mikawa H. Detection of human osteosarcoma-associated antigen(s) by monoclonal antibodies. Cancer Res. 1982 Feb;42(2):654–659. [PubMed] [Google Scholar]
  13. Hu S., Shively L., Raubitschek A., Sherman M., Williams L. E., Wong J. Y., Shively J. E., Wu A. M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996 Jul 1;56(13):3055–3061. [PubMed] [Google Scholar]
  14. Kalofonos H. P., Rusckowski M., Siebecker D. A., Sivolapenko G. B., Snook D., Lavender J. P., Epenetos A. A., Hnatowich D. J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990 Nov;31(11):1791–1796. [PubMed] [Google Scholar]
  15. Kinuya S., Yokoyama K., Konishi S., Hwang E. H., Takayama T., Michigishi T., Tonami N. 201Tl and 99Tcm-human serum albumin for assessment of the effect of hypertensive treatment with angiotensin II infusion on tumour circulation. Nucl Med Commun. 1996 Feb;17(2):160–163. doi: 10.1097/00006231-199602000-00011. [DOI] [PubMed] [Google Scholar]
  16. Kinuya S., Yokoyama K., Konishi S., Tonami N., Hisada K. Effect of induced hypertension with angiotensin II infusion on biodistribution of 111in-labeled monoclonal antibody. Nucl Med Biol. 1996 Feb;23(2):137–140. doi: 10.1016/0969-8051(95)02040-3. [DOI] [PubMed] [Google Scholar]
  17. Kinuya S., Yokoyama K., Yamamoto W., Konishi S., Shuke N., Aburano T., Watanabe N., Takayama T., Michigishi T., Tonami N. Short-period-induced hypertension could improve tumor-to-nontumor ratios of radiolabeled monoclonal antibody. Nucl Med Biol. 1997 Aug;24(6):547–551. doi: 10.1016/s0969-8051(97)00076-0. [DOI] [PubMed] [Google Scholar]
  18. Kobayashi H., Sakahara H., Hosono M., Shirato M., Konishi J., Takahashi J. A., Oda Y., Kikuchi H., Endo K., Kozai Y. Scintigraphic detection of xenografted tumors producing human basic fibroblast growth factor. Cancer Immunol Immunother. 1993 Oct;37(5):281–285. doi: 10.1007/BF01518449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kobayashi H., Sakahara H., Hosono M., Yao Z. S., Toyama S., Endo K., Konishi J. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J Nucl Med. 1994 Oct;35(10):1677–1684. [PubMed] [Google Scholar]
  20. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P. A., Jr Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 3;72(1):77–89. doi: 10.1016/0022-1759(84)90435-6. [DOI] [PubMed] [Google Scholar]
  21. Magnani P., Paganelli G., Modorati G., Zito F., Songini C., Sudati F., Koch P., Maecke H. R., Brancato R., Siccardi A. G. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med. 1996 Jun;37(6):967–971. [PubMed] [Google Scholar]
  22. Meares C. F., McCall M. J., Reardan D. T., Goodwin D. A., Diamanti C. I., McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem. 1984 Oct;142(1):68–78. doi: 10.1016/0003-2697(84)90517-7. [DOI] [PubMed] [Google Scholar]
  23. Nakamura T., Gross M., Yamamuro T., Liao S. K. Identification of a human osteosarcoma-associated glycoprotein with monoclonal antibodies: relationship with alkaline phosphatase. Biochem Cell Biol. 1987 Dec;65(12):1091–1100. doi: 10.1139/o87-142. [DOI] [PubMed] [Google Scholar]
  24. Paganelli G., Magnani P., Zito F., Villa E., Sudati F., Lopalco L., Rossetti C., Malcovati M., Chiolerio F., Seccamani E. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991 Nov 1;51(21):5960–5966. [PubMed] [Google Scholar]
  25. Saga T., Weinstein J. N., Jeong J. M., Heya T., Lee J. T., Le N., Paik C. H., Sung C., Neumann R. D. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 1994 Apr 15;54(8):2160–2165. [PubMed] [Google Scholar]
  26. Sakahara H., Endo K., Nakashima T., Koizumi M., Kunimatsu M., Kawamura Y., Ohta H., Nakamura T., Tanaka H., Kotoura Y. Localization of human osteogenic sarcoma xenografts in nude mice by a monoclonal antibody labeled with radioiodine and indium-111. J Nucl Med. 1987 Mar;28(3):342–348. [PubMed] [Google Scholar]
  27. Sakahara H., Saga T., Endo K., Hattori N., Hosono M., Kobayashi H., Shirato M., Yamamuro T., Toyama S., Arano Y. In vivo instability of reduction-mediated 99mTc-labeled monoclonal antibody. Nucl Med Biol. 1993 Jul;20(5):617–623. doi: 10.1016/0969-8051(93)90030-x. [DOI] [PubMed] [Google Scholar]
  28. Sato H., Sugiyama K., Hoshi M., Urushiyama M., Ishizuka K. Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging. World J Surg. 1995 Nov-Dec;19(6):836–842. doi: 10.1007/BF00299780. [DOI] [PubMed] [Google Scholar]
  29. Suzuki M., Hori K., Abe I., Saito S., Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst. 1981 Sep;67(3):663–669. [PubMed] [Google Scholar]
  30. Tanaka C., Yamamuro T., Masuda T., Tanaka H., Matsumoto M., Kotoura Y., Tsuji T., Toguchida J., Miyama-Inaba M., Ueda M. Recognition of serum alkaline phosphatase by murine monoclonal antibodies against human osteosarcoma cells. Cancer Res. 1986 Sep;46(9):4853–4857. [PubMed] [Google Scholar]
  31. Vaidyanathan G., Bigner D. D., Zalutsky M. R. Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. J Nucl Med. 1992 Aug;33(8):1535–1541. [PubMed] [Google Scholar]
  32. Wakisaka K., Arano Y., Uezono T., Akizawa H., Ono M., Kawai K., Ohomomo Y., Nakayama M., Saji H. A novel radioiodination reagent for protein radiopharmaceuticals with L-lysine as a plasma-stable metabolizable linkage to liberate m-iodohippuric acid after lysosomal proteolysis. J Med Chem. 1997 Aug 1;40(16):2643–2652. doi: 10.1021/jm9606397. [DOI] [PubMed] [Google Scholar]
  33. Yao Z., Zhang M., Kobayashi H., Sakahara H., Nakada H., Yamashina I., Konishi J. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med. 1995 May;36(5):837–841. [PubMed] [Google Scholar]
  34. Yokota T., Milenic D. E., Whitlow M., Wood J. F., Hubert S. L., Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res. 1993 Aug 15;53(16):3776–3783. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES